Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;44(2):295-305.
doi: 10.1038/s41386-018-0171-0. Epub 2018 Aug 7.

Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats

Affiliations

Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats

Shivali Kohli et al. Neuropsychopharmacology. 2019 Jan.

Abstract

The pituitary neuropeptide oxytocin promotes social behavior, and is a potential adjunct therapy for social deficits in schizophrenia and autism. Oxytocin may mediate pro-social effects by modulating monoamine release in limbic and cortical areas, which was investigated herein using in vivo microdialysis, after establishing a dose that did not produce accompanying sedative or thermoregulatory effects that could concomitantly influence behavior. The effects of oxytocin (0.03-0.3 mg/kg subcutaneous) on locomotor activity, core body temperature, and social behavior (social interaction and ultrasonic vocalizations) were examined in adult male Lister-hooded rats, using selective antagonists to determine the role of oxytocin and vasopressin V1a receptors. Dopamine and serotonin efflux in the prefrontal cortex and nucleus accumbens of conscious rats were assessed using microdialysis. 0.3 mg/kg oxytocin modestly reduced activity and caused hypothermia but only the latter was attenuated by the V1a receptor antagonist, SR49059 (1 mg/kg intraperitoneal). Oxytocin at 0.1 mg/kg, which did not alter activity and had little effect on temperature, significantly attenuated phencyclidine-induced hyperactivity and increased social interaction between unfamiliar rats without altering the number or pattern of ultrasonic vocalizations. In the same rats, oxytocin (0.1 mg/kg) selectively elevated dopamine overflow in the nucleus accumbens, but not prefrontal cortex, without influencing serotonin efflux. Systemic oxytocin administration attenuated phencyclidine-induced hyperactivity and increased pro-social behavior without decreasing core body temperature and selectively enhanced nucleus accumbens dopamine release, consistent with activation of mesocorticolimbic circuits regulating associative/reward behavior being involved. This highlights the therapeutic potential of oxytocin to treat social behavioral deficits seen in psychiatric disorders such as schizophrenia.

PubMed Disclaimer

Conflict of interest statement

We declare that, except for income received from their primary employer, no financial support or compensation has been received from any individual or corporate entity over the past three years for research or professional service and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest. The contribution to this work made by SK, MVK, and KCFF was financially supported by Roche. The University of Nottingham BBSRC DTP provided funding for Adele Edwards and Stuart Williams to perform dose–response studies with oxytocin while on laboratory rotations. LJS, TMB, and DA are employed by Hoffmann-la Roche.

Figures

Fig. 1
Fig. 1
Effect of oxytocin (OXY, 0.03, 0.1, and 0.3 mg/kg; s.c., administered after arena habituation) or vehicle (VEH, 0.154 M saline 1 ml/kg) administered according to the protocol shown in a on four occasions at 7 day intervals so that each rat received every dose on b total locomotor activity (LMA, cumulative ambulatory counts, mean ± SEM), and c change in body temperature (from basal recorded 5 min pre injection, mean ± SEM, °C) in adult Lister-hooded rats (n = 12, within-subjects design) recorded in an activity box for 90 min post injection. c *P < 0.05, ***P < 0.001 VEH vs. 0.3 or 0.1 mg/kg OXY; ##P < 0.01, ###P < 0.001, 0.3 mg/kg OXY vs. 0.1 mg/kg OXY; ++P < 0.01 0.3 mg/kg OXY from 0.03 mg/kg OXY; Tukey’s post hoc test
Fig. 2
Fig. 2
Determination of the effect of pre-treatment with the selective V1a receptor antagonist, SR49059 (1 mg/kg), or the selective oxytocin receptor antagonist, L-368,899 (2 mg/kg), according to the experimental protocol shown in a on b the cumulative locomotor ambulatory counts, and c the change in body temperature (°C) over 90 min following injection of oxytocin (OXY, 0.3 mg/kg. s.c., administered 15 min after the antagonist) or vehicle (VEH, 1 ml/kg saline). Data are presented as mean ± SEM, n = 12 per treatment (within-subjects design). In b **P < 0.01 from VEH + VEH controls. In c * P < 0.05 and *** P < 0.001 from VEH + VEH controls, + P < 0.05, ++ P < 0.01 and +++ P < 0.001 0.03 mg/kg OXY from 0.3 mg/kg OXY and ###P < 0.001 0.1 mg/kg OXY from 0.3 mg/kg OXY, following Tukey’s post hoc test
Fig. 3
Fig. 3
a Experimental protocol used to consecutively examine the effect of oxytocin on phencyclidine-induced behavior (this figure), social interaction (Fig. 4), and prefrontal cortex and nucleus accumbens dopamine and 5-HT efflux by microdialysis (Fig. 5), for full details of the methods see Figure S1. Comparative effect of oxytocin (OXY, 0.03–0.1 mg/kg; s.c) and vehicle (VEH, 0.154 M saline 1 ml/kg) on (mean ± SEM) the b time course of phencyclidine (PCP, 5.6 mg/kg; i.p.)-induced locomotor activity (LMA; cumulative counts/5 min epoch), c total ambulatory counts in 1 h (following injection with PCP/VEH), and d change in body temperature (from basal, 5 min prior to injection, °C) in adult Lister-hooded rats recorded in an activity box. In b and c *P < 0.05, **P < 0.01, ***P < 0.001 compared to VEH-SAL; +P < 0.05, ++P < 0.01 compared with VEH-PCP; #P < 0.05, ##P < 0.01 compared with 0.03 mg/kg OXY-PCP; Tukey's post hoc) VEH = saline vehicle, OXY = oxytocin; n = 8 per group (between-subjects design) as indicated VEH-VEH; VEH-PCP; OXY 0.03 mg/kg-PCP; OXY 0.1 mg/kg-PCP
Fig. 4
Fig. 4
Effect of oxytocin (OXY, 0.1 mg/kg; s.c.) and vehicle (VEH, 0.154 M saline 1 ml/kg) on social interaction between two male Lister-hooded rats from different litters paired by similar weight and the same previous drug treatment, recorded over 10 min. a individual behaviors (s), b total time in social interaction (s), c body temperature change from basal (immediately prior to injection), before (45 min post injection) and after the interaction trial (55 min post injection as indicated; °C) and d the number of pro-social 50 kHz ultrasonic vocalizations (USVs) emitted by both rats in each pair. All data are presented as mean ± SEM. e Representative spectrographs showing pro-social 50 kHz USVs emitted from rat pairs defined into three subtypes; flat, step and trill, following Fast Fourier transformation and pattern analysis. a *P = 0.05; Student’s unpaired t-test. c *P < 0.05 from OXY. d Following log10 transformation, *P < 0.05 ***P < 0.001 VEH vs. OXY; Sidak post hoc; VEH = saline vehicle, OXY = 0.1 mg/kg oxytocin; n = 8 pairs/group. NB. A different time scale is used to show ano-genital and body sniffing from other, less frequent, behaviors
Fig. 5
Fig. 5
Comparison of the effects of oxytocin (OXY, 0.1 mg/kg; s.c.) or vehicle (VEH, 0.154 M saline 1 ml/kg) on a dopamine and b serotonin (5-HT) overflow (mean ± SEM, pmol/ml) in the prefrontal cortex (PFC) and nucleus accumbens (NAc) measured by microdialysis, and concomitant c core body temperature (mean ± SEM; °C) in freely-moving rats. a Changes to dopamine from baseline in the PFC (0.0728 pmol/ml) and NAc (0.176 pmol/ml) over the 2 h period. b Changes in 5-HT levels from baseline in the PFC (2.212 pmol/ml) and NAc (3.677 pmol/ml). PFC: Dopamine: n = 7 VEH, n = 6 OXY, 5-HT: n = 7 VEH, n = 6 OXY; NAc: Dopamine: n = 7 VEH, n = 7 OXY, 5-HT: n = 8 VEH, n = 8 OXY; VEH = saline vehicle, OXY = 0.1 mg/kg oxytocin; PFC; Prefrontal Cortex, NAc; Nucleus Accumbens. c *P< 0.05 VEH vs OXY; Sidak post hoc. VEH = saline vehicle, OXY = 0.1 mg/kg oxytocin; n = 8 per treatment group; between-subjects design

Similar articles

Cited by

References

    1. Neumann I, Russell JA, Landgraf R. Oxytocin and vasopressin release within the supraoptic and paraventricular nuclei of pregnant, parturient and lactating rats: a microdialysis study. Neuroscience. 1993;53:65–75. - PubMed
    1. Smith CJ, Poehlmann ML, Li S, Ratnaseelan AM, Bredewold R, Veenema AH. Age and sex differences in oxytocin and vasopressin V1a receptor binding densities in the rat brain: focus on the social decision-making network. Brain Struct Funct. 2017;222:981–1006. - PMC - PubMed
    1. Borthwick AD. Oral oxytocin antagonists. J Med Chem. 2010;53:6525–38. - PubMed
    1. Grinevich V, Knobloch-Bollmann HS, Eliava M, Busnelli M, Chini B. Assembling the Puzzle: pathways of oxytocin signaling in the brain. Biol Psychiatry. 2016;79:155–64. - PubMed
    1. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12:524–38. - PubMed